Car‐t Cell Therapy in Primary Central Nervous System Lymphoma (Pcnsl): The Experience of the French Network for Oculo‐cerebral Lymphomas (Loc)

Alcantara, Marion; Houillier, Caroline; Garff‐Tavernier, Magali Le; Souchet, Laëtitia; Roos‐Weil, Damien; Morel, Véronique; Uzunov, Madalina; Metz, Carole; Nguyen-Quoc, Stéphanie; Jacque, Nathalie; Gauthier, Nicolas; Cann, Marie Le; Norol, Françoise; Willems, Lise; Rascalou, Agathe Waultier; Salanoubat, Célia; Fior, R; Blonski, Marie; Rubio, Marie-Thérès.; Soussain, Carole; Choquet, Sylvain

doi:10.1002/hon.74_2880

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the treatment of PCNSL is mainly based on high-dose methotrexate (HD-MTX). With the development of new therapeutic strategies such as immunotherapy for novel molecular targets, autologous hematopoietic stem cell transplantation, and CART therapy, the PFS and OS of patients with PCNSL have been improved (10)(11)(12)(13)(14), which may lead to changes in the predictive efficacy of previously developed IELSG and MSKCC scores. Therefore, there is an urgent need for a reliable predictive model suitable for the current stage to predict the survival outcome of PCNSL patients, carry out fine risk stratification, and provide a basis for clinical decision-making.…”

Section: Introductionmentioning

confidence: 99%

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Wang

Lyu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPrimary central nervous system lymphoma (PCNSL) is a type of extranodal non-Hodgkin lymphoma. Although there are widely used prognostic scores, their accuracy and practicality are insufficient. Thus, a novel prognostic prediction model was developed for risk stratification of PCNSL patients in our research.MethodsWe retrospectively collected 122 patients with PCNSL from two medical centers in China from January 2010 to June 2022. Among them, 72 patients were used as the development cohort to construct a new model, and 50 patients were used for the validation. Then, by using univariate and multivariate Cox regression analsis and Lasso analysis, the Xijing model was developed and composed of four variables, including lesion number, β2-microglobulin (β2-MG), systemic inflammation response index (SIRI) and Karnofsky performance status (KPS). Finally, we evaluated the Xijing model through internal and external validation.ResultsCompared with the original prognostic scores, the Xijing model has an overall improvement in predicting the prognosis of PCNSL according to the time-dependent area under the curve (AUC), Harrell’s concordance index (C-index), decision curve analysis (DCA), integrated discrimination improvement (IDI) and continuous net reclassification index (NRI). For overall survival (OS) and progression-free survival (PFS), the Xijing model can divide PCNSL patients into three groups, and shows more accurate stratification ability. In addition, the Xijing model can still stratify and predict prognosis similarly better in the elderly with PCNSL and subgroups received high-dose methotrexate (HD-MTX) or Bruton’s tyrosine kinase inhibitors (BTKi). Finally, external validation confirmed the above results.ConclusionsIntegrating four prognostic factors, including imaging findings, tumor burden, systemic inflammation response index, and comprehensive physical condition, we provided a novel prognostic model for PCNSL based on real-world data and evaluated its predictive capacity.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Wang

Lyu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

Schenone

Houillier

Tanguy

et al. 2022

Bone Marrow Transplant

View full text Add to dashboard Cite

Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma

Alcantara

Fuentealba

Soussain

2021

Cancers

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is, mainly, a diffuse large B-cell lymphoma (DLBCL) with a non-germinal center B-cell (non-GCB) origin. It is associated with a poor prognosis and an unmet medical need. Immunotherapy has emerged as one of the most promising areas of research and is now part of the standard treatment for many solid and hematologic tumors. This new class of therapy generated great enthusiasm for the treatment of relapsed/refractory PCNSL. Here, we discuss the challenges of immunotherapy for PCNSL represented by the lymphoma cell itself and the specific immune brain microenvironment. We review the current clinical development from the anti-CD20 monoclonal antibody to CAR-T cells, as well as immune checkpoint inhibitors and targeted therapies with off-tumor effects on the brain microenvironment. Perspectives for improving the efficacy of immunotherapies and optimizing their therapeutic role in PCNSL are suggested.

show abstract

Car‐t Cell Therapy in Primary Central Nervous System Lymphoma (Pcnsl): The Experience of the French Network for Oculo‐cerebral Lymphomas (Loc)

Cited by 3 publications

References 0 publications

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma

Contact Info

Product

Resources

About